American Pain Society (APS) 2012
May 17–19, 2012
(ARUP supply #49204)
- Requires 30 mL urine, which can be collected directly in the testing cup or in a secondary urine collection cup.
- Drug testing will detect up to 12 classes of drugs within 5 minutes of urine collection; results are stable for 60 minutes in most cases.
- A legend is printed on the cup to assist with reading the results.
- If the test result is inconsistent with clinical expectations and pharmacy history, the result should be confirmed using a second, more specific, quantitative technology such as LC-MS/MS or GC-MS.
We can help you harness and protect the power of laboratory data, and position this information to become a leading integrator for growth and clinical performance.
ARUP Pain Management offers:
- Testing products that reduce cost—we focus on cost-effective utilization and do not promote unnecessary tests or inappropriate interpretations
- Unique menu of relevant, quantitation tests
- Serum/plasma option, including LCMS/TOF—detects more than 50 discrete compounds
- Continued menu improvements based on changes in prescribing practices and state-of-the-art analytical methods
- 24/7 operation and excellent turnaround time (average 24–48 hours for screen and 48 hours for confirmation)
- Medical director consultation
- Continued education and client support, including free CME/CEU video lectures and webinars
- Transparency—we listen to clients’ needs and promote ethical, clinically useful approaches
- Nationwide outreach support
- Specimen validity testing by creatinine at no charge for all urine lab screens
Gwen McMillin, PhD
Medical Director, Toxicology and Trace Elements Laboratories
Co-Medical Director, Pharmacogenetics
A Novel Approach to Drug Screening with Blood
Thursday, May 17, 9:00 a.m.
Blood is an ideal specimen for evaluating adherence to therapy in patients who cannot provide urine, to support pharmacokinetic studies, and to reduce the opportunity for specimen adulteration. However, testing for drugs in blood with traditional immunoassay-based technologies is associated with many limitations in sensitivity and specificity. This presentation will describe the improvements in sensitivity and specifi city gained by a novel mass spectrometric approach to drug screening with blood.
Patterns of Opioid Metabolites in Urine–the Buprenorphine Story
Friday, May 18, 9:30 a.m.
Interpretation of urine opioid test results depends on the proportional relationship of parent drugs and drug metabolites. Such patterns are generally used to verify that a patient has been compliant with prescribed therapy, but may also be used to identify when patients have added a drug directly to urine to mimic compliance. This presentation will discuss typical and atypical patterns of buprenorphine and associated metabolite concentrations in urine, relative to the most likely interpretations regarding compliance with therapy.
Gordon Nelson, C(ASCP), NRCC-TC
Vice President, Chemistry Division
Cost-effective Utilization of Urine Drug Testing for Chronic Pain Management Patients
Thursday, May 17, 3:30 p.m.
The costs associated with traditional urine drug testing models for pain management can be excessive due to inappropriate testing, such as reflex confirmation testing for all positive screen results, which is not clinically useful. This presentation will focus on cost-effective strategies that eliminate unnecessary testing and inappropriate interpretations for pain management patients.
Receive a free 4GB USB drive
Come visit us at our booth and receive a free 4GB USB flash drive (while supplies last).